GSK secures another ex-China ADC deal with Hansoh Pharma with $185M upfront
The year of antibody-drug conjugates isn’t done yet, as GSK is adding another licensing partnership with Hansoh Pharma for another ADC with an upfront payment of $185 million. There is also up to $1.525 billion in milestone payments in store for Hansoh, according to a Hong Kong Stock Exchange filing.
In October, the companies announced that GSK will license an ADC from Hansoh, named HS-20089, with an $85 million upfront and a further $1.48 billion in milestone payments.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.